WO2007012661A8 - Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1 - Google Patents

Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1

Info

Publication number
WO2007012661A8
WO2007012661A8 PCT/EP2006/064747 EP2006064747W WO2007012661A8 WO 2007012661 A8 WO2007012661 A8 WO 2007012661A8 EP 2006064747 W EP2006064747 W EP 2006064747W WO 2007012661 A8 WO2007012661 A8 WO 2007012661A8
Authority
WO
WIPO (PCT)
Prior art keywords
medicine
mchr
hydantoin
antagonists
derived compounds
Prior art date
Application number
PCT/EP2006/064747
Other languages
English (en)
Other versions
WO2007012661A1 (fr
Inventor
Fabrice Balavoine
Eric Nicolai
Eric Sartori
Original Assignee
Cerep
Fabrice Balavoine
Eric Nicolai
Eric Sartori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerep, Fabrice Balavoine, Eric Nicolai, Eric Sartori filed Critical Cerep
Publication of WO2007012661A1 publication Critical patent/WO2007012661A1/fr
Publication of WO2007012661A8 publication Critical patent/WO2007012661A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne les composés de formule générale (I) suivante dans laquelle : • Ar1, L1, R1, R2, R3, R4, R5, R6, L2, Q, et n sont tels que définis dans les revendications, ainsi que leur procédé de préparation. L'invention concerne également l'utilisation des composés de formule (I) en tant que médicament, et plus particulièrement pour la préparation d'un médicament destiné au traitement de l'obésité et des maladies associées, d'un médicament coupe-faim et/ou d'un médicament entraînant une perte de poids, d'un médicament destiné au traitement de la dépression et/ou de l'anxiété, et plus généralement d'un médicament destiné au traitement d'une maladie associée aux récepteurs MCH (mélanine concentrating hormone).
PCT/EP2006/064747 2005-07-28 2006-07-27 Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1 WO2007012661A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508064 2005-07-28
FR0508064A FR2889189A1 (fr) 2005-07-28 2005-07-28 Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1

Publications (2)

Publication Number Publication Date
WO2007012661A1 WO2007012661A1 (fr) 2007-02-01
WO2007012661A8 true WO2007012661A8 (fr) 2007-03-29

Family

ID=36470939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064747 WO2007012661A1 (fr) 2005-07-28 2006-07-27 Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1

Country Status (2)

Country Link
FR (1) FR2889189A1 (fr)
WO (1) WO2007012661A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
WO2009097998A1 (fr) * 2008-02-07 2009-08-13 Sanofi-Aventis Imidazolidine-2,4-diones substitués par un arylchalcogeno-arylalkyle, procédé de production, médicaments contenant ces composés et leur utilisation
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
ES2623794T3 (es) * 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
CN101875636B (zh) * 2010-05-18 2012-01-04 浙江大学 咪唑啉-2,4-二酮类衍生物及制备方法和用途
WO2012077655A1 (fr) * 2010-12-07 2012-06-14 塩野義製薬株式会社 Dérivé spiro présentant une activité agoniste de gpr119
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
CN102850252B (zh) * 2011-06-30 2014-08-13 山东大学 一种3,5,5’-三取代乙内酰脲的制备方法
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
DK3177612T3 (da) 2014-08-04 2022-05-16 Nuevolution As Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107417669B (zh) * 2016-05-24 2021-07-06 中国医学科学院药物研究所 3-(1h-吲唑)-四氢嘧啶-2-酮类化合物、其制备方法及其用途
ES2749861T3 (es) 2016-06-13 2020-03-24 Borealis Ag Bandas sopladas por fusión de alta calidad con propiedades de barrera mejoradas
WO2019078920A1 (fr) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. Anti-androgènes destinés au traitement du cancer de la prostate résistant à la castration, non métastatique
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020113088A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés diarylhydantoine et leurs procédés d'utilisation
US20220306640A1 (en) * 2019-09-06 2022-09-29 Ono Pharmaceutical Co., Ltd. Hydantoin derivative
CN112759550A (zh) * 2019-11-04 2021-05-07 上海科技大学 一种平滑受体拮抗剂
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009741C3 (de) * 1970-03-03 1980-07-31 Bayer Ag, 5090 Leverkusen Aromatische Copolyamide
AU2001268958B2 (en) * 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
CA2493458A1 (fr) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Composes d'acide benzoique a substitution ureido et leur utilisation pour la suppression de non-sens et le traitement de maladie

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9481664B2 (en) 2010-02-16 2016-11-01 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof

Also Published As

Publication number Publication date
FR2889189A1 (fr) 2007-02-02
WO2007012661A1 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2007012661A8 (fr) Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1
MA29088B1 (fr) Composes d'indazole-carboxamide.
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
EP1962838A4 (fr) Agonistes de recepteur de farnesoide x
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
DK1713475T3 (da) 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet
TW200630326A (en) Chemical compounds
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
EP1740559A4 (fr) Derives de phenyle 1,3,5-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
PL2026803T3 (pl) Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
PT1235787E (pt) Receptores agonistas beta2 adrenergicos
WO2005121065A3 (fr) Agonistes des recepteurs $g(b)2-adrenergiques diaminiques
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
WO2006052889A3 (fr) Composes de quinolinone-carboxamide
MX2008000255A (es) Activadores de urea glucocinasa.
PT2272824T (pt) Processo para a produção de 2,4¿-metilenodifenildiisocianato muito puro
EP1398029A8 (fr) Derivés de pyrazole,substitués en position 3 ayant une affinité envers le NR3B1 récepteur
MX2007007152A (es) Antagonista de naurocinina-1 con anillo en puente.
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
WO2010071783A8 (fr) Thiazoles en tant que ligands des récepteurs des cannabinoïdes
WO2010011836A3 (fr) Traitement de divers troubles avec de la dihydroxy-7,8 flavone et ses dérivés
WO2007030761A3 (fr) 1,4-diamines acycliques et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06778030

Country of ref document: EP

Kind code of ref document: A1